TY - JOUR
T1 - Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD)
T2 - An Official 2025 ALAT Clinical Practice Guideline
AU - Alberti, María Laura
AU - Auteri, Santiago José
AU - Rojas-Serrano, Jorge
AU - Citera, Gustavo
AU - Buendía-Roldan, Ivette
AU - Babini, Alejandra
AU - Caballero, Carlos Vinicio
AU - Cachafeiro, Antonio
AU - Enghelmayer, Juan Ignacio
AU - Florenzano, Matías
AU - García-Salinas, Rodrigo
AU - Atoche, Vicente Girón
AU - da Mota, Licia María Henrique
AU - Kairalla, Ronaldo Adib
AU - Izcaray, Agustín Acuña
AU - Sanchez-Angarita, Efraín
AU - Xavier, Ricardo Machado
AU - Mejía, Mayra
AU - Storrer, Karin Mueller
AU - Noboa-Sevilla, María Belén
AU - Noriega-Aguirre, Lorena
AU - Rincón-Alvarez, Emily
AU - Rosa, Javier
AU - Tavera, Esther
AU - Gutierrez, Carlos Enrique Toro
AU - Wolff, Verónica
AU - Dieudè, Philippe
AU - Caro, Fabián Matías
N1 - Publisher Copyright:
© 2026 SEPAR
PY - 2026
Y1 - 2026
N2 - Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is a serious extra-articular manifestation, being the second cause of death in patients with RA. Usual interstitial pneumonia is the most frequent form of ILD with several factors resembling idiopathic pulmonary fibrosis. Early recognition of ILD through screening could change treatment strategies and prognosis in patients with RA. In this sense achieving articular activity remission included in the treat to target strategy becomes one of the most important factors not only to diminish the risk for developing ILD but also disease progression. Disease-modifying antirheumatic drugs (DMARDs) became the cornerstone for treating patients with RA-ILD together with antifibrotics for those with progressive pulmonary fibrosis. Therefore, this guideline aims to support early recognition and evidence -based management of this condition.
AB - Rheumatoid arthritis associated interstitial lung disease (RA-ILD) is a serious extra-articular manifestation, being the second cause of death in patients with RA. Usual interstitial pneumonia is the most frequent form of ILD with several factors resembling idiopathic pulmonary fibrosis. Early recognition of ILD through screening could change treatment strategies and prognosis in patients with RA. In this sense achieving articular activity remission included in the treat to target strategy becomes one of the most important factors not only to diminish the risk for developing ILD but also disease progression. Disease-modifying antirheumatic drugs (DMARDs) became the cornerstone for treating patients with RA-ILD together with antifibrotics for those with progressive pulmonary fibrosis. Therefore, this guideline aims to support early recognition and evidence -based management of this condition.
KW - Antifibrotics
KW - Disease-modifying antirheumatic drugs
KW - Guidelines
KW - Interstitial lung disease
KW - Rheumatoid arthritis
KW - Rheumatoid arthritis associated interstitial lung disease
KW - Screening
UR - https://www.scopus.com/pages/publications/105037410340
U2 - 10.1016/j.arbres.2026.04.001
DO - 10.1016/j.arbres.2026.04.001
M3 - Article
AN - SCOPUS:105037410340
SN - 0300-2896
JO - Archivos de Bronconeumologia
JF - Archivos de Bronconeumologia
ER -